Post-earnings recap
Reported
Wed, Jun 3, 2026
EPS actual
$1.55
EPS est.
$1.54
EPS surprise
+0.58%
1-day move
+5.69%
Medtronic's earnings report shows that they met EPS expectations, which likely contributed to the positive stock reaction of 5.69%. However, the lack of revenue data leaves some uncertainty about overall performance. Investors may be encouraged by the EPS beat, but the absence of further details from management could lead to cautious sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.55 | $1.55 | +0.58% |
| Revenue | N/A | $9.6B | N/A |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
Medtronic plc (MDT) is a global leader in medical technology, providing innovative solutions for chronic diseases and surgical procedures. Operating in the health care equipment sector, Medtronic's products play a crucial role in improving patient outcomes and enhancing the quality of life for millions worldwide.
Last quarter
In Q3-2026, Medtronic reported an EPS of $1.36, slightly beating expectations. However, the stock fell 3.10% the following day, indicating market caution despite the positive surprise.
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+1.64%
Avg 1-day reaction
-0.85%
Analysts are generally optimistic, expecting Medtronic to report an EPS of $1.55 and revenue of $9.6 billion. The company has a strong history of beating EPS estimates, which could support a positive market reaction.
Bull case
If Medtronic exceeds the EPS estimate and shows strong revenue growth, it could signal robust demand for its products, leading to increased investor confidence and a potential stock price increase.
Bear case
Conversely, if the company misses its EPS target or provides weak guidance, it could raise concerns about its growth prospects, potentially leading to a decline in the stock price.
Key metrics to watch
Earnings Per Share (EPS)
$1.55EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$9.6BRevenue reflects the overall sales performance and market demand for Medtronic's products, which is vital for growth assessment.
The print will turn on these.
Q1
Will Medtronic's EPS exceed the consensus estimate of $1.55?
A beat on EPS could reinforce investor confidence and lead to a positive stock reaction, especially given the company's history of surprises.
Q2
What guidance will management provide for future revenue growth?
Clear guidance on revenue growth is crucial for assessing the company's ability to navigate market challenges and capitalize on opportunities.
—
Est. EPS
$2.28
Est. Rev
$1.8B
Impl. Move
±8.2%
Why consensus could be wrong
The consensus may underestimate Medtronic's ability to innovate and capture market share, especially in emerging markets where demand for health care technology is rising.
Supporting evidence
The company's recent product launches have received positive feedback, suggesting stronger-than-expected sales.
Options pricing indicates a higher expected move than historical averages, hinting at potential surprises.
Medtronic's strong history of beating EPS estimates suggests that analysts may be underestimating its performance.
Key risk
If Medtronic's revenue growth exceeds $9.7 billion, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will be closely scrutinized for signs of growth amid a competitive health care landscape.
Bull confirmed if
An EPS of $1.60 or higher would confirm strong operational performance and growth potential.
Bear confirmed if
An EPS below $1.52 would indicate potential weakness in demand or operational challenges.
What the market is pricing for the move.
Implied Move
±5.32%
Historical Avg
±3.8%
The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility based on the results.
Options are pricing ±5.3% while MDT has averaged ±3.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
25.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Medtronic beats expectations and raises guidance, history suggests a potential stock increase of around 4.69% based on past performance.
In line / cautious
If results are in line with expectations but management is cautious, the stock may experience a muted reaction, reflecting uncertainty.
Miss
A miss on EPS could lead to a decline of approximately 3.14%, as seen in previous quarters when expectations were not met.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
3
0 buys·3 sells
Members
3
House only
Est. Notional
$17,003.00–$80,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Net selling
1 trade
Net selling
1 trade
Net selling
Recent Transactions
Traded Aug 24, 2026 · disclosed Sep 1, 2026
$15,001.00–$50,000.00
Traded Jul 30, 2026 · disclosed Aug 14, 2026
$1,001.00–$15,000.00
Traded May 15, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.